Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines
Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduct...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/15/9/563 |
| _version_ | 1797576579491037184 |
|---|---|
| author | Sonal Gupta Sabine Pellett |
| author_facet | Sonal Gupta Sabine Pellett |
| author_sort | Sonal Gupta |
| collection | DOAJ |
| description | Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen–host interactions, offer exciting and promising avenues for the development of new and improved vaccines. |
| first_indexed | 2024-03-10T21:54:06Z |
| format | Article |
| id | doaj.art-e6f6f32900c846d6a6a2bb01969fcdec |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-10T21:54:06Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-e6f6f32900c846d6a6a2bb01969fcdec2023-11-19T13:16:06ZengMDPI AGToxins2072-66512023-09-0115956310.3390/toxins15090563Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin VaccinesSonal Gupta0Sabine Pellett1Department of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706, USADepartment of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706, USAVaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen–host interactions, offer exciting and promising avenues for the development of new and improved vaccines.https://www.mdpi.com/2072-6651/15/9/563recombinant vaccinesvaccinetoxintoxoidbotulismtetanus |
| spellingShingle | Sonal Gupta Sabine Pellett Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines Toxins recombinant vaccines vaccine toxin toxoid botulism tetanus |
| title | Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines |
| title_full | Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines |
| title_fullStr | Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines |
| title_full_unstemmed | Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines |
| title_short | Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines |
| title_sort | recent developments in vaccine design from live vaccines to recombinant toxin vaccines |
| topic | recombinant vaccines vaccine toxin toxoid botulism tetanus |
| url | https://www.mdpi.com/2072-6651/15/9/563 |
| work_keys_str_mv | AT sonalgupta recentdevelopmentsinvaccinedesignfromlivevaccinestorecombinanttoxinvaccines AT sabinepellett recentdevelopmentsinvaccinedesignfromlivevaccinestorecombinanttoxinvaccines |